HOME >> MEDICINE >> NEWS
Study identifies potential drug target for Huntington's disease

An enzyme known to be critical for the repair of damaged cells and the maintenance of cellular energy may be a useful target for new strategies to treat Huntington's disease (HD) and other disorders characterized by low cellular energy levels. In the August issue of Chemistry & Biology, a research team from the MassGeneral Institute for Neurodegenerative Disease (MIND) describes their discovery of a novel inhibitor of Poly (ADP-ribose) polymerase (PARP1) and their findings that PARP1 inhibitors can protect HD-affected cells from damage in laboratory assays.

"While PARP1 is essential for the repair of damaged DNA, we also know that, if overactivated, it can cause cell death by excessive energy depletion," says Aleksey Kazantsev, PhD, director of the MIND High Throughput Drug Screening Laboratory, who led the current study. "It has recently been shown that neurons from patients with Huntington's appear to be energy-deficient, so we hypothesized that modest stresses that would be tolerated by healthy cells could send HD cells below a viable energy threshold and that blocking PARP1 activation could be protective."

To test this hypothesis the MIND researchers first ran a computer search of their small-molecule library for potential novel inhibitors of PARP1, searching for those with structural similarities to known inhibitors. "Safety and efficacy of human drugs depends on many factors, so it's hard to predict which inhibitor would be most effective against a specific disorder. The more diverse novel inhibitors can be identified, the more chances there are of developing safe and effective drugs," Kazantsev explains.

Two candidate molecules were identified as potential PARP1 inhibitors based on their structure, and both of them were confirmed to inhibit the enzyme's activity in an in vitro assay. However, when tested using cultured human and rat cells, only one of the candidate molecules, K245-14, successfully prevented the death o
'"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
28-Jul-2006


Page: 1 2

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study identifies potential drug target for Huntington disease

(Date:10/31/2014)... Monica Williams-Murphy MD , advanced care ... the chaos that can occur for people who have ... of Americans who come into the emergency department facing ... for the moment and so are their families." She ... a catalyst for a family to get the critical ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
(Date:10/31/2014)... 31, 2014 Today, Analysts Review ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,Celgene Corporation Research Reports ,On October 23, 2014, Celgene ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
Cached News: